Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.42
+5.9%
$3.03
$2.56
$6.44
$628.29M0.184.27 million shs4.86 million shs
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
$0.00
$0.00
$0.00
N/AN/AN/A99,000 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-1.52%-0.31%+5.21%+19.19%-12.23%
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.42
+5.9%
$3.03
$2.56
$6.44
$628.29M0.184.27 million shs4.86 million shs
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
$0.00
$0.00
$0.00
N/AN/AN/A99,000 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-1.52%-0.31%+5.21%+19.19%-12.23%
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.67
Moderate Buy$14.33319.10% Upside
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ALT, DEV, ATQT, and SAAS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Reiterated RatingBuy
6/24/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Reiterated RatingSell (D-)
6/22/2026
Altimmune, Inc. stock logo
ALT
Altimmune
Initiated CoverageOutperform$10.00
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$40K16,631.46N/AN/A$2.44 per share1.40
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.09M-$0.78N/AN/AN/A-214,860.98%-31.41%-26.96%11/5/2026 (Estimated)
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest ALT, DEV, ATQT, and SAAS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.1355-$0.12+$0.0155-$0.12$0.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
0.07
26.78
26.78
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
1.60%
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
50194.52 million191.41 millionOptionable
Subscribe Technologies Inc.  stock logo
SAAS
Subscribe Technologies
147,000N/AN/ANot Optionable

Recent News About These Companies

10+ Best SaaS Marketing Agencies That You Need in 2026
SaaS News
How to build SaaS product
The Future of Healthcare: Innovations in Healthcare SaaS
Re-Engineering SaaS For The Agentic Era
Latest SaaS News: Trends, Funding, and Expert Analysis
Why Online Casino Tech Is Starting to Resemble SaaS Platforms
SaaS price hikes put CIOs’ budgets in a bind
Cybercrime Goes SaaS: Renting Tools, Access, and Infrastructure

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$3.42 +0.19 (+5.88%)
As of 04:00 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Subscribe Technologies stock logo

Subscribe Technologies CNSX:SAAS

Subscribe Technologies Inc. develops, acquires, operates, and manages software as a service (SaaS) business in Canada. The company offers bContact.com, a cloud based business management solution that provides access to an integrated set of business management tools, such as customer relationship management, accounting and banking, invoicing and billing, quotations, and others for small and medium sized companies. It also provides ServerHawk.com, a SaaS Website analysis, SEO, and marketing tool for marketing professionals, business owners, and Web developers; and FileQ.com, an electronic file sharing and storage service that enable users to access content in real time. In addition, the company offers SiteSafe.io, an Internet security service that assists IT professionals in maintaining and managing networks, including the detection of viruses, worms, Trojans, and other malware injected on Websites. Further, it engages in the development of LenderTech.com, a cloud based SaaS loan management utility solution for banks, financial institutions, mortgage lending facilitators, and micro-finance lenders. The company was formerly known as Surrey Capital Corp. and changed its name to Subscribe Technologies Inc. in January 2017. Subscribe Technologies Inc. was incorporated in 2010 and is based in Vancouver, Canada.